DK0804584T3 - Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler - Google Patents

Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler

Info

Publication number
DK0804584T3
DK0804584T3 DK95936537T DK95936537T DK0804584T3 DK 0804584 T3 DK0804584 T3 DK 0804584T3 DK 95936537 T DK95936537 T DK 95936537T DK 95936537 T DK95936537 T DK 95936537T DK 0804584 T3 DK0804584 T3 DK 0804584T3
Authority
DK
Denmark
Prior art keywords
sequences
prophylactic
therapeutic
hepatitis
diagnostic agents
Prior art date
Application number
DK95936537T
Other languages
Danish (da)
English (en)
Inventor
Geert Maertens
Lieven Stuyver
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26137782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0804584(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of DK0804584T3 publication Critical patent/DK0804584T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK95936537T 1994-10-21 1995-10-23 Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler DK0804584T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94870166 1994-10-21
EP95870076 1995-06-28
PCT/EP1995/004155 WO1996013590A2 (en) 1994-10-21 1995-10-23 New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents

Publications (1)

Publication Number Publication Date
DK0804584T3 true DK0804584T3 (da) 2002-09-23

Family

ID=26137782

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95936537T DK0804584T3 (da) 1994-10-21 1995-10-23 Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler

Country Status (12)

Country Link
US (2) US7129337B1 (de)
EP (2) EP1076092A3 (de)
JP (2) JPH10507643A (de)
AT (1) ATE218617T1 (de)
AU (1) AU702436B2 (de)
BR (1) BR9509421A (de)
CA (1) CA2201703A1 (de)
DE (1) DE69526973T3 (de)
DK (1) DK0804584T3 (de)
ES (1) ES2176342T5 (de)
PT (1) PT804584E (de)
WO (1) WO1996013590A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620075D0 (en) * 1996-09-26 1996-11-13 Dynal As Method
US7078500B1 (en) * 1998-01-30 2006-07-18 The General Hospital Corporation Genetic immunization with nonstructural proteins of hepatitis C virus
WO1999054735A1 (en) 1998-04-17 1999-10-28 Innogenetics N.V. Improved immunodiagnostic assays using reducing agents
WO1999055385A2 (de) * 1998-04-28 1999-11-04 Wolfgang Bergter Radioimmunpharmaka zur therapie der hepatitis c
DE69922958T3 (de) * 1998-06-24 2008-06-26 Innogenetics N.V. Hcv hüllproteine partikel : verwendung für therapeutische impfung
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
ES2296803T3 (es) * 2000-08-17 2008-05-01 Tripep Ab Vacunas que contienen ribavirina.
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
ES2596753T3 (es) * 2003-08-29 2017-01-11 Fujirebio Europe N.V. Nuevo clado del virus de la hepatitis C y secuencias prototipo del mismo
CA2552949C (en) 2004-01-07 2012-10-02 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
RU2267496C2 (ru) 2004-01-15 2006-01-10 Сергей Иванович Черныш Противоопухолевые и антивирусные пептиды
EP1888751A2 (de) * 2005-05-25 2008-02-20 Tripep Ab Nichtstrukturelles ns3/4a-fusionsgen des hepatitis-c-virus
US7465561B2 (en) 2005-06-30 2008-12-16 Roche Molecular Systems, Inc. Probes and methods for hepatitis C virus typing using single probe analysis
CA2632822C (en) 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
KR20180043854A (ko) 2006-07-14 2018-04-30 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
WO2008022401A1 (en) * 2006-08-25 2008-02-28 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Recombinant hcv e2 glycoprotein
US20110136678A1 (en) 2006-10-20 2011-06-09 Erwin Sablon Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
US20090325145A1 (en) 2006-10-20 2009-12-31 Erwin Sablon Methodology for analysis of sequence variations within the hcv ns5b genomic region
ES2587014T3 (es) 2006-11-24 2016-10-20 Ac Immune S.A. Derivados de N-(metil)-piridin-2-amina para el tratamiento de enfermedades asociadas a proteínas amiloides o de tipo amiloide
CA2690434C (en) 2007-06-12 2018-05-22 Ac Immune S.A. Monoclonal anti beta amyloid antibody
PL2170389T3 (pl) 2007-06-12 2015-03-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
EA018102B1 (ru) * 2007-08-09 2013-05-30 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ идентификации генотипа и подтипа вируса гепатита c на биологическом микрочипе
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
EP2650308A3 (de) 2007-10-05 2014-11-12 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenerkrankungen
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
EP2311823A1 (de) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridinverbindungen zur Behandlung von Krankheiten im Zusammenhang mit Amyloidproteinen oder zur Behandlung von Augenkrankheiten
CN102939282B (zh) 2010-04-16 2015-12-02 Ac免疫有限公司 用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物
US20110256064A1 (en) 2010-04-16 2011-10-20 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
US8962241B2 (en) * 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス.エー. 安全で機能的なヒト化抗βアミロイド抗体
CN103502272B (zh) 2010-10-07 2016-06-15 Ac免疫有限公司 识别Tau的磷酸化特异抗体
KR101854943B1 (ko) 2010-10-26 2018-05-04 에이씨 이뮨 에스.에이. 소수성 부분을 통해 변형된 펩티드를 포함하는 리포솜 기반 구조체
MX354662B (es) 2011-10-07 2018-03-14 Ac Immune Sa Anticuerpos fosfoespecificos que reconocen la tau.
US9657091B2 (en) 2012-04-05 2017-05-23 Ac Immune S.A. Humanized tau antibody
CN104583235B (zh) 2012-06-08 2019-03-01 苏特罗生物制药公司 含位点特异非天然氨基酸残基的抗体、其制备和使用方法
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CN102766701B (zh) * 2012-07-04 2016-05-04 福州泰普生物科学有限公司 丙型肝炎病毒基因分型的试剂盒及方法
SG11201501464TA (en) 2012-08-31 2015-03-30 Sutro Biopharma Inc Modified amino acids comprising an azido group
CA2902910A1 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
EP2994754B1 (de) * 2013-05-10 2018-07-25 The United States of America, as represented by The Secretary, Department of Health and Human Services Zusammensetzungen und verfahren zur simultanen detektion des hcv antigens bzw. antikörpers
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
AU2014317035B2 (en) 2013-09-05 2020-02-27 Ab2 Bio Sa IL-18 binding protein (IL-18BP) in inflammatory diseases
EP3055298B1 (de) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
UA128752C2 (uk) 2015-03-05 2024-10-16 Аб2 Біо Са Фармацевтична композиція для лікування асоційованого з il-18 захворювання або порушення
US11098107B2 (en) 2016-06-15 2021-08-24 Sutro Biopharma, Inc. Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
GB201807367D0 (en) 2018-05-04 2018-06-20 Univ Newcastle Biomarker
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2021224432A1 (en) 2020-05-06 2021-11-11 Ab2 Bio Sa Il-18 binding protein (il-18bp) in respiratory diseases
EP3943097A1 (de) 2020-07-24 2022-01-26 AB2 Bio SA Car-t-zelltherapie
EP4486367A1 (de) 2022-03-04 2025-01-08 AB2 Bio SA Il-18-bindendes protein (il-18bp) zur behandlung von vexas
EP4547701A1 (de) 2022-07-01 2025-05-07 Sutro Biopharma, Inc. Il-12-mutanten mit reduzierter toxizität, zusammensetzungen davon und verfahren zur verwendung davon
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT54896A (en) 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
JP3156200B2 (ja) 1989-09-15 2001-04-16 国立予防衛生研究所長 新規のhcv分離株
DE4040339C2 (de) 1989-12-18 1999-07-08 Wellcome Found Virales Agens
FI913068A7 (fi) 1990-06-25 1991-12-26 The Res Foundation For Microbial Ei-A-, ei-B-hepatiittiviruspartikkelit
RO117267B1 (ro) 1991-05-08 2001-12-28 Chiron Corp Secventa de acid nucleic si peptida codificata de aceasta, pentru diagnostic si tratament
WO1993000365A2 (en) * 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
EP0532167A3 (en) 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
DK0608261T3 (da) * 1991-09-13 2003-03-17 Chiron Corp Sammensætninger med immunreaktivt hepatitis C virus polypeptid
ATE231557T1 (de) 1991-11-21 2003-02-15 Common Services Agency Detektion des hepatis-c virus.
JPH07508423A (ja) * 1993-04-27 1995-09-21 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム C型肝炎ウイルス遺伝子型の新しい配列及び治療及び診断用薬剤としてのその使用
JPH06319563A (ja) * 1993-05-13 1994-11-22 Imuno Japan:Kk C型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにc型 肝炎ウイルス遺伝子型判定方法
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines

Also Published As

Publication number Publication date
JPH10507643A (ja) 1998-07-28
US20020183508A1 (en) 2002-12-05
ATE218617T1 (de) 2002-06-15
EP1076092A3 (de) 2001-03-28
CA2201703A1 (en) 1996-05-09
ES2176342T5 (es) 2010-02-09
EP0804584B1 (de) 2002-06-05
BR9509421A (pt) 1997-09-30
AU3844095A (en) 1996-05-23
EP0804584A1 (de) 1997-11-05
WO1996013590A3 (en) 1996-08-15
EP1076092A2 (de) 2001-02-14
WO1996013590A2 (en) 1996-05-09
US7129337B1 (en) 2006-10-31
JP2005118044A (ja) 2005-05-12
EP0804584B2 (de) 2008-07-09
DE69526973T2 (de) 2003-01-02
US6974864B2 (en) 2005-12-13
AU702436B2 (en) 1999-02-18
ES2176342T3 (es) 2002-12-01
DE69526973T3 (de) 2010-01-07
PT804584E (pt) 2002-11-29
DE69526973D1 (de) 2002-07-11

Similar Documents

Publication Publication Date Title
DK0804584T3 (da) Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler
FI946066A0 (fi) Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina
DE69334357D1 (de) Nachweis und Typisierung das Hepatitis C Virus (HCV) mittels 5'UTR und NS5 Nukleinsäuresequenzen
RU93058449A (ru) Hcv геномные последовательности для диагностических и терапевтических целей
MX9801715A (es) Secuencia novedosa en el extremo 3' del genoma del virus de la hepatitis c, y su uso en diagnostico y en la preparacion de composiciones terapeuticas.
ID28224A (id) Virus sindrom perusakan multisistemik paska-pemutusan dari babi
ATE318309T1 (de) Hcv-spezifische peptide, mittel dazu und ihre verwendung
PT698216E (pt) Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
DK1542732T3 (da) Fusionsproteiner af Mycobacterium tuberculosis
DE69232906T2 (de) Detektion des Hepatis-C Virus.
NO308621B1 (no) Polynukleotider som er nyttige for screening av hepatitis C virus samt anvendelse av disse
NO20000514L (no) Oligonukleotidprimere for effektiv multipleksdeteksjon av Hepatitt C-virus (HCV) og human immunosviktvirus (HIV) og metoder for anvendelse derav
NO20020573D0 (no) Sekvens
DK0551275T3 (da) Non-A non-B sekvenser
DK0638364T3 (da) Testbestik
DK0491713T3 (da) Rubella El-peptider og C-peptider
ATE389021T1 (de) Rrekombinante proteine eines pakistani-stammes von hepatitis-e-virus, ihre verwendung in diagnotischen verfahren und als impfstoff
NO20024325L (no) Rensede hepatitt C-viruskappeproteiner for diagnose og terapeutisk anvendelse
IT1270941B (it) Peptidi di hcv e loro usi.
TW369600B (en) Antigenic peptides for grouping hepatitis C virus, kit comprising the same and methods for its grouping the same